We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A Chicago jury has ruled that Endo Pharmaceuticals didn’t violate antitrust laws by paying Impax $112 million to delay the release of a generic that would compete against Opana ER, Endo’s extended-release version of the opioid painkiller oxymorphone.